Summary Information

Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names 5-iodo-2'deoxyuridine, IDU, IUDR. (B135.49.w49, B553.44.w44)
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • Inhibitor of DNA synthesis. (B135.49.w49)
  • Thymidine analogue, active against DNA viruses (herpesviruses, poxviruses). (B553.44.w44)
  • Inside the host cell it is phosphorylated then incorporated into DNA during synthesis. (B553.44.w44)
    • Also affects host cell DNA synthesis - incorporated into host DNA. (B135.49.w49)
    • DNA containing idoxuridine is thought to be more susceptible to breakage, and if transcribed results in faulty proteins. (B553.44.w44)
  • Inhibits herpes simplex virus replication in the cornea. (B135.49.w49)
  • Used as a 0.1% solution or 0.5% ointment. (B135.49.w49)
  • Not effective in the treatment of herpes simplex or varicella-zoster skin lesions. B135.49.w49
  • Allergic contact dermatitis can occur. (B135.49.w49)
  • Not suitable for systemic use due to toxicity. (B135.49.w49)
    • Side effects include leucopaenia, hepatotoxocoity and GIT toxicity. (B553.44.w44)

Return to Top of Page